Stockscreener 앱 받기
2.24%
전일 마감가:
$3.12
열려 있는:
$3.12
하루 거래량:
2.99M
Relative Volume:
0.71
시가총액:
$593.15M
수익:
$36,000
순이익/손실:
$-91.08M
주가수익비율:
-3.253
EPS:
-0.9376
순현금흐름:
$-71.67M
1주 성능:
-3.48%
1개월 성능:
+16.86%
6개월 성능:
-24.13%
1년 성능:
-30.68%
1일 변동 폭
$2.95
$3.135
1주일 범위
$2.93
$3.30
52주 변동 폭
$2.56
$6.4399
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.05 | 593.15M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 업그레이드 | Goldman | Sell → Neutral |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Altimmune advances research to address alcohol use disorder and liver disease link - Traders Union
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
Altimmune, Inc. Actuals & Estimates (DUS:3G0) - TradingView
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing CatalystUpgrade (ALT) - Seeking Alpha
Here's why you should add Altimmune stock to your portfolio now - MSN
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Yahoo Finance
5 Overlooked Penny Stocks to Buy Right Now - Insider Monkey
ETFs Investing in Altimmune, Inc. Stocks - TradingView
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus - Sahm
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2000 Value Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2500 Value Benchmark - marketscreener.com
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Price to book forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Price to book forward of Altimmune, Inc. – SWB:3G0 - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to sales forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Price to sales forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to earnings forward of Altimmune, Inc. – SWB:3G0 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Price to earnings forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Price to sales forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Altimmune, Inc. Actuals & Estimates (NASDAQ:ALT) - TradingView
Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Enterprise value to EBIT forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Enterprise value to EBITDA forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
ALT Forecast — Price Target — Prediction for 2027 - TradingView
A2N5Z6 Forecast — Price Target — Prediction for 2027 - TradingView
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Insider Monkey
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Altimmune Inc (ALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALT Initiated Coverage by Leerink PartnersRating Set to Outpe - GuruFocus
Leerink Partners Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Altimmune stock coverage citing liver drug data By Investing.com - Investing.com South Africa
Leerink initiates Altimmune stock coverage citing liver drug data - Investing.com
Leerink Partners Initiates Altimmune at Outperform With $10 Price Target - marketscreener.com
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
2.64%
자본화:
|
볼륨(24시간):